BioWorld Asia

Sep. 30, 2009

Qiagen's $130M Purchase of DxS a 13X Profit for Investors

LONDON - There was a record return for all the investors in companion diagnostics pioneer DxS Ltd., when the company was acquired last week by Qiagen NV for a total of up to $130 million. (BioWorld International) Read More

J&J Buys $444M Stake in Crucell; Focus on Flu Vaccine and mAbs

Repair Qualities of Macrophages, Hope for Muscle Regeneration

Rhucin Gains Ground as It Nears EMEA Action in HAE

NicOx Submits Naproxcinod's NDA; Celebrex in Crosshairs

Abbott Makes $6.6B Cash Bid for Solvay's Drug Unit

Marinomed, Bioalvo Collaborate on Drug Discoveries from the Sea

On the March: Vaccines Make it Big After H1N1 Scare

2009 Vaccine Deals

CHMP Gives Unanimous Backing for Yondelis in Ovarian Cancer

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 8, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

Bial-Portela discovers new OX1 receptor antagonists

BioWorld Science

Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...

Woman taking medication for mental illness

Autobahn on the fast track with bipolar thyroid agonist

BioWorld

Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...